A new cannabis genetics paper cataloged 227 volatile terpenes across six cultivars. The fun part is what those compounds reveal about flower, genes, and why your nose keeps finding more than a THC label can say.
Everyone reported that the federal hemp ban slipped to December 11. It hasn't passed the House, and the delay is narrower than the coverage suggests: it turns on whether a molecule is capable of being naturally produced, not on how it was actually made. What that sorts, and what it strands.
Two clinical trials of lion's mane both gave subjects three grams a day. One of them used ten times more mushroom than the other. Seventeen years of research, seven small trials, and still no agreement on what a dose is. Plus Curaleaf goes hostile on Aurora, and Yale prices federal legalization.
PsiDeR was built to answer whether the NHS could run a psilocybin trial at all. It could. The 12.92-point depression result everyone reported is a secondary outcome, and the researchers said so plainly. Their press office left that part out. Plus: the Senate blinks on hemp.
Past-month cannabis use among Minnesota teens fell from 13% to 5% across twelve years of steadily looser law, and the predicted spike never came. The decline also never reached Native, LGBTQ+ or low-income students, who were three times more likely to use in 2013 and still are today.
Researchers pooled 28 studies covering 937 CBD products and found just 31.3 percent contained what the label claimed. Topicals came in at 13.8 percent. Plus undisclosed THC, synthetic cannabinoids, heavy metals, and why the number on the box can be wrong in four different ways.
While psychedelic mushrooms fight for legal status, their boring cousins quietly became a near-$85 billion wellness industry. What the science on lion's mane and reishi actually shows — and where the marketing gets ahead of it.
Psilocybin, LSD, DMT, mescaline, ayahuasca — five different molecules. A Nature Medicine mega-analysis of 267 people and 500+ brain scans found they all leave the same fingerprint: they don't quiet the brain, they connect it.
Humans have used peyote for 5,700 years, yet mescaline is the psychedelic neuroscience knows least. A new Northeastern brain scan shows the oldest trip has a signature all its own — and Big Pharma just bet up to $3.8B on its molecular cousins.
For years, home growers prized a potent magic mushroom called Natal Super Strength. Nobody had ever named it. New DNA work shows it is a separate species, and its family tree pushes the origins of the world's favorite psychedelic mushroom back more than a million years.
What if the trip was never the point? A new class of compounds promises the brain-rewiring of psychedelics without the hallucination, and the first non-tripping antidepressant is heading for trials you can run from your own couch.
Scientists finally caught the munchies in the act. A new study shows cannabis turns up the brain's reward for food, spikes the hunger hormone, and sharpens taste. The same circuit could feed people who can't eat.